Patent Showdown: Hologic's Court Win Over Siemens Rocks Mammography Market

MARLBOROUGH, MA – June 16, 2026 – The intersection of innovation, law, and healthcare has been thrown into sharp relief by a legal earthquake shaking the European medical technology sector. In a stunning victory for Hologic, Inc., the newly formed Unified Patent Court (UPC) has ordered rival Siemens Healthineers to halt sales and execute a complete recall and destruction of its latest mammography systems across three key European countries. The ruling, issued on June 10, 2026, is more than a corporate win; it is a powerful demonstration of Europe's new legal framework and a critical inflection point in the high-stakes race to advance breast cancer detection.

At the heart of the case is Hologic’s European Patent EP 2 352 431, which protects the company's pioneering “Focusing Technology” used in its Envision™ Platform. The UPC’s Düsseldorf Local Division found that Siemens’ MAMMOMAT B.brilliant systems, specifically their “Flying Focal Spot” technology, directly infringed upon Hologic’s protected innovation. The court's response was swift and severe: an immediate, sweeping injunction prohibiting Siemens from making, offering, or even storing the infringing systems in Germany, France, and the Netherlands. The order goes further, mandating a full recall from hospitals and clinics, destruction of the machines, and a complete refund to customers, setting a dramatic precedent for patent enforcement.

A Landmark Ruling with Cross-Border Clout

For legal observers and intellectual property strategists, the Hologic-Siemens decision is a landmark case that validates the power of the Unified Patent Court. Established to create a single, streamlined patent litigation system across participating EU member states, the UPC's effectiveness was a subject of intense speculation. This ruling puts much of that speculation to rest. The court’s ability to issue a cross-border injunction that takes effect simultaneously in multiple major markets is precisely the kind of potent enforcement patentees have long desired.

“This ruling is a decisive validation of the strength and originality of Hologic’s innovation,” said Essex Mitchell, Chief Operating Officer at Hologic, in a statement following the victory. The company’s strategic maneuvering highlights the new legal landscape; Hologic had initially opted this specific patent out of the UPC system in May 2023 but astutely withdrew that opt-out in November 2024, positioning itself to leverage the court’s unique power. The court's rejection of Siemens’ defense on grounds of proportionality further signals that the UPC will not easily dilute the strength of a valid patent.

This case underscores a fundamental shift for MedTech companies operating in Europe. According to legal experts, IP strategy in 2026 and beyond must now account for the UPC’s capacity for rapid, broad enforcement. The era of fighting costly, parallel patent battles in each individual country may be drawing to a close, replaced by a high-stakes, unified front that can determine market access across a continent in a single judgment.

The Technology at the Heart of the Dispute

Behind the legal battle lies a technological race to produce the clearest, most accurate images for detecting breast cancer at its earliest stages. Hologic, a dominant force with an estimated 70% of the global 3D mammography market, built its reputation on technologies like its Genius™ 3D platform. The patent in question protects a key component of its next-generation Envision™ system, which received FDA approval in 2024. This “Focusing Technology” is designed to enhance image sharpness, a critical factor in improving diagnostic confidence and reducing the need for repeat scans.

Siemens Healthineers, a formidable competitor in the broader medical imaging space, launched its MAMMOMAT B.brilliant system in late 2023. It was the company's first major platform redesign in over a decade and was positioned as a significant leap forward. However, the UPC found that its core “Flying Focal Spot” feature was too close to Hologic’s patented method. The dispute highlights the fine line between competitive innovation and patent infringement. As one industry analyst noted, “In a field this specialized, where incremental improvements in image resolution can translate directly into lives saved, protecting the intellectual property that drives that R&D is paramount.”

This is not the first time this specific patent has been tested. Siemens challenged its validity at the European Patent Office (EPO) in 2019, but the opposition was rejected, a decision that was upheld on appeal as recently as April 2024. This history of validation likely strengthened Hologic’s position before the UPC.

Market Tremors and a Competitive Vacuum

The court’s injunction is set to cause significant tremors in the European mammography market, which was valued at over $542 million in 2025 and is projected to grow robustly. Germany, France, and the Netherlands represent substantial portions of this market, driven by national screening programs and the rising adoption of advanced 3D tomosynthesis. By forcing the recall and destruction of the MAMMOMAT B.brilliant, the ruling effectively removes a key competitor from the field, at least temporarily.

This creates a significant vacuum that Hologic is well-positioned to fill. However, other major players, including GE Healthcare, Fujifilm, and Philips, will also be eyeing the opportunity to gain market share. For Siemens Healthineers, the financial and reputational costs are substantial. Beyond the immediate costs of the recall, refunds, and future damages, the company must also provide Hologic with detailed sales records dating back to 2018, opening its books on the commercial scale of the infringement. The company has a 60-day window to appeal the decision, but the immediate commercial damage is already done.

Ripple Effects in Clinics and Patient Care

While executives and lawyers analyze the long-term strategic implications, the most immediate impact will be felt in clinics and hospitals across the three affected nations. Healthcare providers who invested in the new Siemens MAMMOMAT B.brilliant systems are now faced with a mandatory recall. This presents a logistical nightmare, requiring them to decommission newly installed equipment and navigate the process of securing refunds and sourcing replacements. The disruption could lead to postponed screening appointments and create backlogs in patient care, a critical concern in oncology where early detection is everything.

This case serves as a stark reminder that the world of innovation does not exist in a vacuum. The battles fought in courtrooms over patent rights have tangible consequences for the delivery of healthcare. While Hologic rightfully argues that protecting innovation is essential for future advancements, the short-term disruption for providers and patients is an unavoidable side effect. As hospitals scramble to secure alternative systems, the ruling underscores the complex interplay between commercial competition, intellectual property law, and the vital work of saving lives. The industry will be watching closely to see how Siemens responds and how quickly the market adapts to this sudden, court-ordered shift.